CTRI/2021/06/034065
Not yet recruiting
未知
Cardiovascular disease manifestations with special emphasis on myocarditis-in moderate to severe COVID-19 patients undergoing treatment in the ccu of a tertiary care hospital in West Bengal India
Dr Swati Datta0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: B99-B99- Other infectious diseasesHealth Condition 2: B338- Other specified viral diseases
- Sponsor
- Dr Swati Datta
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Age more than 18 years
- •2\. Laboratory confirmed COVID\-19 patients
- •3\. SpO2 less than 94%
- •4\. Patients on different modalities of oxygen therapy
- •5\. Patients with radiologically confirmed pneumonia
- •6\. ARDS or Acute Respiratory Failure
- •1\. Age more than 18 years
- •2\. COVID\-19 RTPCR negative
- •3\. SpO2 less than 94%
- •4\. Patients on different modalities of oxygen therapy
Exclusion Criteria
- •1\. Moribund patient with septicemia with or without multiorgan dysfunction
- •2\. Patient unwilling to participate in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Cardiac- and vascular disease (-abnormalities) as underlying cause of premature birth.premature birth100103941001027310003216NL-OMON39237Academisch Medisch Centrum300
Not yet recruiting
Not Applicable
Cardiac Effects In Moderate ToSevere COVID-19 Patients Receiving Treatment InCritical Care Unit Of A Tertiary Care Hospital,West BengalCTRI/2021/06/034469MEDICAL COLLEGE KOLKATA
Completed
Not Applicable
Delivering enhanced cardiovascular disease and hypertension care through private health facilities in PakistaHypertension / Cardiovascular DiseaseCirculatory SystemAtherosclerotic cardiovascular diseaseISRCTN34381594niversity of Leeds (UK)912
Completed
Not Applicable
Concurrent Treatment of Cardiovascular Disease in Peritoneal Dialysis (PD) patients. Multi-center Randomized Clinical Study with Aldosterone blockade (spironolactone) and Angiotensin Receptor Blocker (ARB) or Angiotensin-Converting-Enzyme Inhibitor (ACEI).End-Stage Renal Disease (ESRD) and Cardio-Vascular Disease (CVD)JPRN-UMIN000000492agoya University160
Recruiting
Phase 3
ong term impact of RAS inhibition on cardio-renal outcomes: a comparative trial of angiotensin converting enzyme inhibitors, angiotensin receptor blockers or combined therapy with both agents in patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.Cardiovascular - Normal development and function of the cardiovascular systemMetabolic and Endocrine - DiabetesACTRN12607000333415Consorzio Mario Negri Sud2,100